Analyst consensus rating
Acumen Pharmaceuticals Analyst Rating: Strong Buy
ABOS is rated Strong Buy by 5 analysts with a $7.40 target. As of 2026-08-26.
Direct answer
Acumen Pharmaceuticals's consensus rating is Strong Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.40.
Forecast evidence checked August 26, 2026.
Get free Acumen Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $2.95
- Average price target
- $7.40
- High price target
- $10.00
- Low price target
- $4.00
- Low target gap
- +35.6%
- Target upside
- +150.8%
- High target gap
- +239%
- Target range width
- 203.4%
- Consensus rating
- Strong Buy
- Analysts
- 5
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Acumen Pharmaceuticals?
Acumen Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $7.40.
How far are Acumen Pharmaceuticals's low and high targets from the recorded price?
The low target implies +35.6%, while the high target implies +239%.
How many analysts are included in Acumen Pharmaceuticals's consensus?
The verified consensus includes 5 analysts.
How is Acumen Pharmaceuticals's target upside or downside calculated?
The average target of $7.40 is divided by the recorded price of $2.95, then one is subtracted to produce +150.8%. This does not guarantee a future return.
When was Acumen Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.